Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2852W HIGH $1.80
Volume
114.52 K
Value Traded
55.58 K
Short % Float
0.98%
+1.28%Week
+0.97%1 Month
+3.06%3 Month
-68.38%6 Month
-99.84%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.91 M
EPS (TTM)
-0.46
P/E Ratio
-
Ent. Value
-1.90 M
Total Shares
21.77 M
Float Shares
20.77 M
Insiders
4.59%
Institutions
4.29%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
SNGX Catalyst Timeline
Dated clinical, regulatory and corporate events for Soligenix, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Soligenix, Inc.
1053Total events
7Upcoming
232Tier-1 (high impact)
2010 to 2028Coverage
Upcoming catalysts 2
Event history 50
◆Other Regulator MilestoneEx-US Regulatory
Application for CEPI funding for Bundibugyo virus vaccine development due
Bundibugyo virus vaccinesource ↗
●Other Regulator MilestoneEx-US Regulatory
Application for CEPI funding for Bundibugyo vaccine
Bundibugyo virussource ↗
▼Program DiscontinuationHyBryte™FiledCorporate
HyBryte development program terminated
cutaneous T-cell lymphoma (CTCL)source ↗
●Other Regulator MilestoneEx-US Regulatory
Highlighted platform compatibility for Bundibugyo vaccine
Bundibugyo virussource ↗
▼Trial Stopped FutilityHyBryte™FiledTrial
Phase 3 FLASH2 trial halted for futility after interim efficacy analysis
cutaneous T-cell lymphomasource ↗
▼Interim AnalysisHyBryte™FiledTrial
Interim efficacy analysis completed by Data Monitoring Committee
cutaneous T-cell lymphomasource ↗
▲PublicationHyBryte™FiledPresentation
Positive results of comparability study of HyBryte vs Valchlor published in Oncology and Therapy
cutaneous T-cell lymphomasource ↗
◆Interim AnalysisHyBryte™FiledTrial
Pre-specified blinded interim analysis of FLASH2 study expected
cutaneous T-cell lymphomasource ↗
▼Trial DiscontinuedHyBryte™FiledTrial
FLASH2 trial halted for futility after interim analysis
cutaneous T-cell lymphomasource ↗
▼Interim AnalysisHyBryte™FiledTrial
Interim efficacy analysis completed by Data Monitoring Committee
cutaneous T-cell lymphomasource ↗
◆Topline ReadoutHyBryte™FiledClinical Data
Top-line results from FLASH2 study
cutaneous T-cell lymphoma (CTCL)source ↗
▼Trial Stopped FutilityHyBryte™FiledTrial
FLASH2 trial halted for futility based on DMC interim analysis
cutaneous T-cell lymphoma (CTCL)source ↗
▲Topline ReadoutSGX302Clinical Data
Top-line results for last cohort of four patients in Phase 2a trial of SGX302 for psoriasis
mild-to-moderate psoriasissource ↗
▲EU Orphan DesignationSGX945Ex-US Regulatory
European Commission grants orphan drug designation to SGX945 for Behçet's Disease
Behçet's Diseasesource ↗
◆Oral PresentationHyBryte™FiledPresentation
Phase 2 Investigator-Initiated Real-World Study Evaluating Topical Hypericin Ointment Photodynamic Therapy for Early-Stage Mycosis Fungoides/CTCL
cutaneous T-cell lymphoma (CTCL)source ↗
◆Poster PresentationHyBryte™FiledPresentation
Results from a Pilot Study of HyBryte™ (topical synthetic hypericin) versus Valchlor® (mechlorethamine) in the Treatment of CTCL
cutaneous T-cell lymphoma (CTCL)source ↗
▲Enrollment MilestoneHyBryte™FiledTrial
First safety review milestone achieved for FLASH2 study
cutaneous T-cell lymphoma (CTCL)source ↗
●Oral PresentationHyBryte™FiledPresentation
Presentation of findings from supportive trials with HyBryte™ at US Cutaneous Lymphoma Consortium Workshop
cutaneous T-cell lymphoma (CTCL)source ↗
▲PublicationHyBryte™FiledPresentation
Publication of clinical summary in Expert Opinion on Investigational Drugs
cutaneous T-cell lymphoma (CTCL)source ↗
▲MHRA ILAPSGX945Ex-US Regulatory
SGX945 granted Promising Innovative Medicine (PIM) designation by MHRA
Behçet's Diseasesource ↗
▲EU Orphan DesignationSGX945Ex-US Regulatory
Positive opinion from EMA COMP for orphan drug designation for SGX945 in Behçet's Disease
Behçet's Diseasesource ↗
▼Program DiscontinuationHyBryte™FiledCorporate
HyBryte development program under evaluation; potential discontinuation
cutaneous T-cell lymphomasource ↗
▲EU Orphan DesignationSGX945Ex-US Regulatory
Orphan drug designation from EMA for SGX945
Behçet's Diseasesource ↗
▲MHRA ILAPSGX945Ex-US Regulatory
Promising Innovative Medicine (PIM) designation from MHRA for SGX945
Behçet's Diseasesource ↗
▲Full ResultsSGX945Clinical Data
Phase 2a results published in Rheumatology (Oxford)
Behçet's Diseasesource ↗
●PublicationSGX945Presentation
Publication of Phase 2a proof of concept study results of SGX945 in Rheumatology (Oxford)
Behçet's Diseasesource ↗
▲Topline ReadoutSGX302Clinical Data
Top-line results of Phase 2a study of SGX302 in mild-to-moderate psoriasis
mild-to-moderate psoriasissource ↗
▲Enrollment CompleteSGX302Trial
Enrollment completed for Cohort 3 of Phase 2a psoriasis study
mild-to-moderate psoriasissource ↗
●Full ResultsSGX302Clinical Data
Extended results of ongoing Phase 2a trial of SGX302 for psoriasis
mild-to-moderate psoriasissource ↗
◆Trial InitiationHyBryte™FiledTrial
Final confirmatory trial for HyBryte in CTCL is currently running
cutaneous T-cell lymphomasource ↗
◆Trial InitiationHyBryte™FiledTrial
Conducting final confirmatory clinical study for HyBryte in CTCL
cutaneous T-cell lymphomasource ↗
▲Full ResultsSGX302Clinical Data
Extended results of Phase 2a trial of SGX302 for psoriasis announced
mild-to-moderate psoriasissource ↗
◆Topline ReadoutSGX302Clinical Data
Top-line results from Phase 2a clinical trial of SGX302 in mild-to-moderate psoriasis
mild-to-moderate psoriasissource ↗
◆Enrollment UpdateHyBryte™FiledTrial
Enrollment update for confirmatory Phase 3 study of HyBryte in early-stage CTCL
early-stage cutaneous T-cell lymphoma (CTCL)source ↗
◆Enrollment CompleteHyBryte™FiledTrial
Enrollment completion of FLASH2 study
cutaneous T-cell lymphoma (CTCL)source ↗
▲Enrollment MilestoneHyBryte™FiledTrial
Completed enrollment of 50 patients for interim analysis in FLASH2 study
cutaneous T-cell lymphomasource ↗
▲Enrollment CompleteHyBryte™FiledTrial
Completed enrollment of 50 patients for interim analysis in confirmatory Phase 3 FLASH2 trial of HyBryte™
cutaneous T-cell lymphoma (CTCL)source ↗
▲DSMB ReviewHyBryte™FiledTrial
First DMC meeting concluded no safety concerns for HyBryte in CTCL Phase 3 trial
cutaneous T-cell lymphoma (CTCL)source ↗
▲DSMB ReviewHyBryte™FiledTrial
First DMC meeting concludes no safety concerns for FLASH2 study
cutaneous T-cell lymphomasource ↗
◆Enrollment UpdateHyBryte™FiledTrial
Enrollment update expected in 4Q2025
cutaneous T-cell lymphomasource ↗
Past FDA Catalysts and PDUFA Decisions
How SNGX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-26 | HyBryte™ (SGX301, topical synthetic hypericin) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C40 / 100
Pipeline Score
$3M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.3x
rNPV / MCap
Top 40%
Micro Cap(rank 265 of 660)
Percentile Rank
Soligenix, Inc. carries a moderate pipeline score (40/100), with $1.0B risk-adjusted pipeline value, led by SGX301 (synthetic hypericin) in Psoriasis (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SGX301 (synthetic hypericin) Small moleculeCompletedNCT05872854 | Cutaneous T Cell Lymphoma | Phase 3 | COMPLETED | 179 | Dec 22, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every SNGX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| HyBryte™ Fast TrackOrphan | cutaneous T-cell lymphoma | Phase 3 | 2026-04-28 | the study was recommended to halt for futilityRead More | Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell LymphomaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SCHABER CHRISTOPHER JDirector, Officer (CHAIRMAN, CEO AND PRESIDENT) | Buy | 15,132 15,511 held | $1.32 | 10/02/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in SNGX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SNGX for Q2 2026. | ||||
SNGX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SNGX ranks across every disease it competes in
Competitive Position is a premium feature
See how SNGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSNGX News
SNGXSoligenix Announces Recent Updates and Second Quarter 2026 Financial Results
Soligenix, Inc. announced its second quarter 2026 financial results, revealing no revenue and a net loss of $2.0 million. The company discontinued the HyBryte™ development program following disappointing Phase 3 study results but remains optimistic about its other pipeline products, particularly SGX945 for Behçet's disease. Soligenix is exploring strategic options to enhance stockholder value, including potential partnerships and funding opportunities.
Read more →SNGXSoligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
Soligenix, Inc. is applying for funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a thermostable vaccine for the Bundibugyo virus. The company has previously shown promising results with its vaccine platform, demonstrating robust immune responses and protection in non-human primates. However, the success of the funding application remains uncertain, especially following the discontinuation of another clinical trial.
Read more →SNGX▲ +31.5%on this news· ran to +133% by day 3
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
Soligenix, Inc. is advancing a thermostable vaccine for the Bundibugyo virus, which is linked to the recent outbreak in Congo. Collaborating with Dr. Axel Lehrer, the company has demonstrated the vaccine's efficacy in preclinical studies. The platform aims to simplify vaccine distribution in endemic areas, but its development hinges on securing adequate funding.
Read more →SNGXSoligenix Announces Recent Updates and First Quarter 2026 Financial Results
Soligenix, Inc. reported disappointing results from its FLASH2 study, leading to a halt for futility. Despite initial success with HyBryte™, the extended treatment did not yield expected results. The company is evaluating strategic options, including potential mergers and advancing other therapies like SGX945 for Behçet's Disease. Financially, Soligenix reported a net loss of $2.8 million for Q1 2026.
Read more →SNGX▼ -70.3%on this news
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. announced that the Phase 3 FLASH2 trial of HyBryte™ for cutaneous T-cell lymphoma was halted due to an interim analysis indicating futility. Despite previous success in a related study, the current trial did not show expected efficacy after 18 weeks. The company plans to analyze the data further and explore potential next steps, including discussions with regulatory agencies.
Read more →SNGXPositive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Soligenix, Inc. announced positive results from a comparability study of HyBryte™ against Valchlor® for treating cutaneous T-cell lymphoma (CTCL). The study, published in Oncology and Therapy, showed that 60% of HyBryte™ patients achieved treatment success compared to 20% for Valchlor®. HyBryte™ was well tolerated, with no adverse events reported, highlighting its potential as a safer alternative for CTCL treatment.
Read more →SNGX▲ +6.3%on this newsshared move
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Soligenix, Inc. reported its financial results for 2025, highlighting key milestones and upcoming clinical trials. The company anticipates interim analysis results from the Phase 3 FLASH2 trial of HyBryte™ for CTCL in Q2 2026. Additionally, dusquetide received orphan drug designation for Behçet's Disease, while SGX302 showed clinical benefits in psoriasis. However, the company faced a net loss of $11.1 million and no revenues for the year.
Read more →SNGXSoligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
Soligenix, Inc. has been granted orphan drug designation for SGX945 by the European Commission for the treatment of Behçet's Disease. This designation follows positive Phase 2a clinical trial results showing efficacy and safety. The orphan designation provides marketing exclusivity in the EU and aids in product development support. The company aims to address the unmet medical needs of patients suffering from this chronic condition.
Read more →SNGXHyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
Soligenix, Inc. announced that findings from trials of HyBryte™ for cutaneous T-cell lymphoma will be presented at the US Cutaneous Lymphoma Consortium Workshop. The results indicate positive outcomes in comparison to Valchlor® and highlight the treatment's efficacy and safety. Dr. Ellen Kim will present the findings, showcasing the potential of HyBryte™ as a long-term treatment option.
Read more →SNGXSoligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Soligenix, Inc. announced the publication of a clinical summary for HyBryte™ in 'Expert Opinion on Investigational Drugs'. The summary details positive results from clinical trials for treating cutaneous T-cell lymphoma (CTCL). Dr. Poligone emphasizes HyBryte™'s unique mechanism and safety profile, while Soligenix looks forward to completing patient enrollment in the ongoing FLASH2 Phase 3 study.
Read more →SNGXSoligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
Soligenix, Inc. announced that SGX945 (dusquetide) has received the Promising Innovative Medicine designation from the UK's MHRA for treating Behçet's Disease. This designation is a prerequisite for inclusion in the Early Access to Medicines Scheme, which allows severely ill patients to access new medicines earlier. Clinical studies have shown that SGX945 is likely to offer major advantages over existing treatment methods for Behçet's Disease. The company aims to leverage this designation to expedite the availability of SGX945 to affected patients.
Read more →SNGXSoligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
Soligenix, Inc. announced that the European Medicines Agency's Committee for Orphan Medicinal Products provided a positive recommendation for orphan drug designation of SGX945 for Behçet's Disease. This follows promising Phase 2a clinical results showing efficacy and safety. The next step is ratification by the European Commission, which could enhance market exclusivity in the EU.
Read more →SNGXSoligenix to Present at BIO Investment & Growth Summit
Soligenix, Inc. announced that its CEO, Dr. Christopher J. Schaber, will present at the BIO Investment & Growth Summit on March 2. The summit will feature various programs and meetings aimed at fostering investment in biopharmaceutical innovations. Soligenix is focused on developing treatments for rare diseases and has several ongoing clinical programs.
Read more →SNGXSoligenix Details Recent Progress and Upcoming Milestones
Soligenix, Inc. provided an update on its late-stage pipeline and strategic options for 2026. The company anticipates significant sales from its products, particularly HyBryte™, with a projected market opportunity exceeding $90 million in the U.S. However, it faces uncertainties regarding clinical trial outcomes and regulatory approvals.
Read more →SNGXSoligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
Soligenix, Inc. announced positive top-line results from its Phase 2a study of SGX302 for mild-to-moderate psoriasis. The optimized gel formulation demonstrated clinical success, with patients showing significant improvements in psoriasis severity indices. The treatment was well tolerated, indicating its potential as a safe option for psoriasis management.
Read more →SNGXPositive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet
Soligenix, Inc. has announced positive results from a Phase 2a study of SGX945 for treating Behçet's disease. The study revealed that SGX945 effectively reduced oral ulcers in seven out of eight patients, with benefits reportedly lasting beyond the treatment period. The results compared favorably to a Phase 3 trial of apremilast, highlighting the potential for SGX945 as an effective maintenance therapy. The company plans to further develop SGX945 to improve patient access through home-based administration.
Read more →SNGXSoligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
Soligenix Inc. is making strides in developing therapies for rare diseases, particularly with its HyBryte treatment for cutaneous T-cell lymphoma, which is nearing the final trial phase. The company is addressing significant unmet medical needs as chronic illnesses among older Americans increase. With supportive government funding, Soligenix is well-positioned to advance its innovative treatments.
Read more →SNGXSoligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
Soligenix Inc. is advancing its treatment HyBryte for cutaneous T-cell lymphoma (CTCL) as part of its efforts to address rare diseases. The company is in the final stages of clinical studies before seeking global marketing approval. This initiative aligns with increasing demands for new therapies in the aging population affected by rare diseases.
Read more →About Soligenix, Inc.
Headquarters29 EMMONS DRIVE, PRINCETON, NJ, 08540
BIOPHARMAWATCH ELITE PLUS
Trade the next SNGX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime